241 related articles for article (PubMed ID: 29977004)
1. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice.
Zhou K; Zhang JW; Wang QZ; Liu WY; Liu JL; Yao L; Cai MM; Ni SY; Cai QY; Wang GJ; Zhou F
Acta Pharmacol Sin; 2019 Apr; 40(4):556-562. PubMed ID: 29977004
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
[TBL] [Abstract][Full Text] [Related]
3. Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients.
Liu M; Li H; Wang X; Jing L; Jiang P; Li Y
Cancer Med; 2020 Apr; 9(8):2660-2673. PubMed ID: 32073228
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis.
Zhang Z; Yang W; Ma F; Ma Q; Zhang B; Zhang Y; Liu Y; Liu H; Hua Y
Drug Deliv; 2020 Dec; 27(1):691-702. PubMed ID: 32397840
[TBL] [Abstract][Full Text] [Related]
5. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Kim SJ; Jung KH; Son MK; Park JH; Yan HH; Fang Z; Kang YW; Han B; Lim JH; Hong SS
Cancer Lett; 2017 Sep; 403():339-353. PubMed ID: 28688971
[TBL] [Abstract][Full Text] [Related]
6. Normalizing Tumor Vessels To Increase the Enzyme-Induced Retention and Targeting of Gold Nanoparticle for Breast Cancer Imaging and Treatment.
Xiao W; Ruan S; Yu W; Wang R; Hu C; Liu R; Gao H
Mol Pharm; 2017 Oct; 14(10):3489-3498. PubMed ID: 28845990
[TBL] [Abstract][Full Text] [Related]
7. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.
Chen L; Cheng X; Tu W; Qi Z; Li H; Liu F; Yang Y; Zhang Z; Wang Z
Cell Oncol (Dordr); 2019 Oct; 42(5):679-690. PubMed ID: 31325096
[TBL] [Abstract][Full Text] [Related]
8. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model.
Ohta M; Kawabata T; Yamamoto M; Tanaka T; Kikuchi H; Hiramatsu Y; Kamiya K; Baba M; Konno H
Surg Today; 2009; 39(12):1046-53. PubMed ID: 19997799
[TBL] [Abstract][Full Text] [Related]
9. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
10. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
11. N-Terminal Modification of the Tetrapeptide Arg-Leu-Tyr-Glu, a Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Antagonist, Improves Antitumor Activity by Increasing its Stability against Serum Peptidases.
Yun JA; Kim J; Baek YY; Park W; Park M; Kim S; Kim T; Choi S; Jeoung D; Lee H; Won MH; Kim JY; Ha KS; Kwon YG; Kim YM
Mol Pharmacol; 2019 Dec; 96(6):692-701. PubMed ID: 31594790
[TBL] [Abstract][Full Text] [Related]
12. Normalization of Tumor Vasculature by Oxygen Microbubbles with Ultrasound.
Ho YJ; Chu SW; Liao EC; Fan CH; Chan HL; Wei KC; Yeh CK
Theranostics; 2019; 9(24):7370-7383. PubMed ID: 31695774
[TBL] [Abstract][Full Text] [Related]
13. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
14. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
[TBL] [Abstract][Full Text] [Related]
15. Apatinib-loaded nanoparticles inhibit tumor growth and angiogenesis in a model of melanoma.
Zhang J; Liu P; Zhang Z; Han J; Yang X; Wang A; Zhang X
Biochem Biophys Res Commun; 2020 Jan; 521(2):296-302. PubMed ID: 31668370
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound-Targeted Microbubble Destruction Enhances Inhibitory Effect of Apatinib on Angiogenesis in Triple Negative Breast Carcinoma Xenografts.
Hong D; Yang J; Guo J; Zhang Y; Chen Z
Anal Cell Pathol (Amst); 2021; 2021():8837950. PubMed ID: 33959473
[TBL] [Abstract][Full Text] [Related]
18. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy.
Shen G; Li Y; Du T; Shi G; Dai L; Chen X; Zheng R; Li W; Su X; Zhang S; Wei Y; Yang S; Deng H
Neoplasma; 2012; 59(5):486-93. PubMed ID: 22668017
[TBL] [Abstract][Full Text] [Related]
19. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.
Lin Y; Zhai E; Liao B; Xu L; Zhang X; Peng S; He Y; Cai S; Zeng Z; Chen M
Oncotarget; 2017 Feb; 8(7):11990-12002. PubMed ID: 28061477
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
